The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hindmarsh, E. J.
Right arrow Articles by Marks, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hindmarsh, E. J.
Right arrow Articles by Marks, R. M.
The Journal of Immunology, 1998, 160: 6128-6136.
Copyright © 1998 by The American Association of Immunologists

Complement Activation Occurs on Subendothelial Extracellular Matrix In Vitro and Is Initiated by Retraction or Removal of Overlying Endothelial Cells1

Elizabeth J. Hindmarsh and Rory M. Marks2

Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109

Vascular endothelium is continuously exposed to plasma complement, which could generate a potent proinflammatory signal if activated on the vascular wall. Normal endothelium, however, expresses an anti-inflammatory phenotype, which includes resistance to complement fixation. As activated endothelium converts to a proinflammatory phenotype, we investigated the effect of cytokines on endothelial susceptibility to complement fixation. Cytokine-treated HUVEC were exposed to human serum as a source of complement, and C3 deposition was quantified. IL-1ß and TNF-{alpha} in combination with IFN-{gamma} markedly increased endothelial C3 deposition; however, immunofluorescence microscopy revealed that the endothelial cells had retracted, and that bound C3 was concentrated not on cells but in areas of exposed subendothelial extracellular matrix (ECM). Studies with cell-free ECM indicated that complement activation required only ECM exposure and was independent of cellular activation. C3 deposition on ECM was reproduced by reconstituting the alternative pathway, which generated a stable C3 convertase on ECM, but not on endothelial cells. C3b and iC3b were identified on ECM exposed to purified alternative pathway components and serum, respectively. In conditions associated with endothelial disruption, exposure of subendothelial ECM could induce complement fixation and contribute to inflammation and vascular damage.




This article has been cited by other articles:


Home page
 BloodHome page
A.-l. Stahl, F. Vaziri-Sani, S. Heinen, A.-C. Kristoffersson, K.-H. Gydell, R. Raafat, A. Gutierrez, O. Beringer, P. F. Zipfel, and D. Karpman
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation
Blood, June 1, 2008; 111(11): 5307 - 5315.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. R. Kinderlerer, F. Ali, M. Johns, E. A. Lidington, V. Leung, J. J. Boyle, S. S. Hamdulay, P. C. Evans, D. O. Haskard, and J. C. Mason
KLF2-dependent, Shear Stress-induced Expression of CD59: A NOVEL CYTOPROTECTIVE MECHANISM AGAINST COMPLEMENT-MEDIATED INJURY IN THE VASCULATURE
J. Biol. Chem., May 23, 2008; 283(21): 14636 - 14644.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
R. M. Cowell, J. M. Plane, and F. S. Silverstein
Complement Activation Contributes to Hypoxic-Ischemic Brain Injury in Neonatal Rats
J. Neurosci., October 15, 2003; 23(28): 9459 - 9468.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Zhang, C. Gerhardinger, and M. Lorenzi
Early Complement Activation and Decreased Levels of Glycosylphosphatidylinositol-Anchored Complement Inhibitors in Human and Experimental Diabetic Retinopathy
Diabetes, December 1, 2002; 51(12): 3499 - 3504.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. T. Tran, S. J. Hodgkinson, N. Carter, M. Killingsworth, S. T. Spicer, and B. M. Hall
Attenuation of Experimental Allergic Encephalomyelitis in Complement Component 6-Deficient Rats Is Associated with Reduced Complement C9 Deposition, P-Selectin Expression, and Cellular Infiltrate in Spinal Cords
J. Immunol., May 1, 2002; 168(9): 4293 - 4300.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Jain, A. Karadag, B. Fohr, L. W. Fisher, and N. S. Fedarko
Three SIBLINGs (Small Integrin-Binding LIgand, N-linked Glycoproteins) Enhance Factor H's Cofactor Activity Enabling MCP-like Cellular Evasion of Complement-mediated Attack
J. Biol. Chem., April 12, 2002; 277(16): 13700 - 13708.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Aukrust, L. Gullestad, K. T. Lappegard, T. Ueland, H. Aass, L. Wikeby, S. Simonsen, S. S. Froland, and T. E. Mollnes
Complement Activation in Patients With Congestive Heart Failure: Effect of High-Dose Intravenous Immunoglobulin Treatment
Circulation, September 25, 2001; 104(13): 1494 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. A. Lidington, D. O. Haskard, and J. C. Mason
Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury
Blood, October 15, 2000; 96(8): 2784 - 2792.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Mason, H. Yarwood, K. Sugars, B. P. Morgan, K. A. Davies, and D. O. Haskard
Induction of Decay-Accelerating Factor by Cytokines or the Membrane-Attack Complex Protects Vascular Endothelial Cells Against Complement Deposition
Blood, September 1, 1999; 94(5): 1673 - 1682.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.